Evaxion Biotech Extends Phase 2 Trial for Cancer Vaccine EVX-01

Evaxion Biotech ( (EVAX) ) has shared an update.

Evaxion Biotech A/S announced on February 25, 2025, the extension of its phase 2 trial for the personalized cancer vaccine EVX-01 by an additional year, aiming to enhance the clinical data package. The trial, initially planned for two years, is designed to treat advanced melanoma and utilizes Evaxion’s AI-Immunology™ platform. The extension is expected to provide further insights into treatment effects and immune response durability, with the two-year data readout anticipated in the second half of 2025. The trial has shown promising results, with a significant reduction in tumor target lesions and positive patient responses, potentially strengthening Evaxion’s position in the oncology field.

More about Evaxion Biotech

Evaxion Biotech A/S is a pioneering TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company leverages its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion’s clinical-stage oncology pipeline includes personalized vaccines, and it also has a preclinical pipeline targeting infectious diseases with high unmet medical needs.

YTD Price Performance: -42.26%

Average Trading Volume: 2,461,096

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $2.86M

See more data about EVAX stock on TipRanks’ Stock Analysis page.